Acrivon Therapeutics Common Stock Statistics
Share Statistics
Acrivon Therapeutics Common Stock has 31.35M
shares outstanding. The number of shares has increased by 1.54%
in one year.
| Shares Outstanding | 31.35M |
| Shares Change (YoY) | 1.54% |
| Shares Change (QoQ) | 0.69% |
| Owned by Institutions (%) | 60.39% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8,927 |
| FTD / Avg. Volume | 1.64% |
Short Selling Information
The latest short interest is 1.39M, so 4.44% of the outstanding
shares have been sold short.
| Short Interest | 1.39M |
| Short % of Shares Out | 4.44% |
| Short % of Float | 11.87% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -25.25 and the forward
PE ratio is -0.47.
Acrivon Therapeutics Common Stock's PEG ratio is
0.28.
| PE Ratio | -25.25 |
| Forward PE | -0.47 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 11.51 |
| P/FCF Ratio | -29.72 |
| PEG Ratio | 0.28 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Acrivon Therapeutics Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.55,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.55 |
| Quick Ratio | 10.55 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,074,080 |
| Employee Count | 75 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -86.36% in the
last 52 weeks. The beta is 1.9, so Acrivon Therapeutics Common Stock's
price volatility has been higher than the market average.
| Beta | 1.9 |
| 52-Week Price Change | -86.36% |
| 50-Day Moving Average | 2.85 |
| 200-Day Moving Average | 6.04 |
| Relative Strength Index (RSI) | 29.29 |
| Average Volume (20 Days) | 544,793 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -89.2M |
| Net Income | -80.56M |
| EBITDA | -79.55M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.24 |
Full Income StatementBalance Sheet
The company has 39.82M in cash and 3.65M in
debt, giving a net cash position of 36.17M.
| Cash & Cash Equivalents | 39.82M |
| Total Debt | 3.65M |
| Net Cash | 36.17M |
| Retained Earnings | -196.98M |
| Total Assets | 196.59M |
| Working Capital | 164.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -65.67M
and capital expenditures -2.77M, giving a free cash flow of -68.44M.
| Operating Cash Flow | -65.67M |
| Capital Expenditures | -2.77M |
| Free Cash Flow | -68.44M |
| FCF Per Share | -0.2 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
